Sign up Australia
Proactive Investors - Run By Investors For Investors
Why invest in NRT?
Novogen: THE INVESTMENT CASE

Novogen: Access latest PPT from Proactive's CEO Sessions

Dr James Garner talked clinical-stage programs with investors.
Novogen: Access latest PPT from Proactive's CEO Sessions
INVESTMENT OVERVIEW: NRT The Big Picture
Dr James Garner, chief executive officer, Novogen

Novogen’s (ASX:NRT, NASDAQ:NVGN) chief executive officer, Dr James Garner, joined Proactive's CEO Sessions in Melbourne on Tuesday, 11th April.

Novogen is an emerging oncology drug developer with two clinical-stage programs.

The company's value proposition is to partner with big pharma for late-stage development to bring to market.

ACCESS THE FULL PRESENTATION HERE



Register here to be notified of future NRT Company articles
View full NRT profile

Novogen Timeline

Newswire
August 05 2015

Related Articles

stylised picture with web icons meant to denote a web search
May 11 2016
Searchbolt, the business being bought, was spun-off from ETX when the latter was listed on stock market in 2007
Bankroll.jpg
March 02 2017
The new funds will be used to expand the pre-clinical and early-clinical development of the company’s immuno-oncology drug, Clevegen
brokerreport.jpg
January 25 2017
Analyst Vadim Alexandre, of the company’s broker Northland Capital, said Wednesday’s update provided “better visibility” on the trial timetable.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use